Previous 10 | Next 10 |
– Clinical programs on track for multiple topline data releases in 2020 – – Entered clinical trial collaboration with Merck to evaluate KEYTRUDA ® (pembrolizumab) in combination with GB1275 in advanced solid tumors – – Company to host confe...
– Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation – – GB1275 granted Orphan Drug Designation for the treatment of pancreatic cancer by the U.S. Food and Drug Administration – – Preclinical data for GB1275 fe...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB002, the Company’...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB001, the Company’...
- First-in-human Phase 1/2 trial of GB1275 to be featured in trial-in-progress poster - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inf...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its third quarter 2019 financial re...
I decided to finalize my bearish thesis on Gossamer Bio ( GOSS ) and put it all in one article. Gossamer Bio, Inc. is San Diego based biotech start-up. The lead drug candidate of the company, GB001 , is being evaluated at Phase-2b for the treatment of moderate-to-severe eosinophilic asthm...
Cellectis S.A. (NASDAQ: CLLS ) resumed with Buy rating and $28 (151% upside) price target at Guggenheim. Shares up 3% premarket. More news on: Cellectis S.A., Gossamer Bio, Inc., Health Catalyst, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Most investors know what they're getting into when buying a stake in an early-stage pharmaceutical company. Anyone needing a reminder only has to look at the stock chart of Gossamer Bio (NASDAQ: GOSS) . The company raised $291 million from an initial public offering (IPO) in February...
Shares of Gossamer Bio (NASDAQ: GOSS) fell as much as 14.6% at the market open on Tuesday, then soared as much as 21.4% less than an hour later. The biotech stock was up by 6.7% as of 11:20 a.m. EDT. Why such wild swings? Novartis (NYSE: NVS) announced that its experimental asthma ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-24 17:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for GOSS on June 24, 2024 04:04PM ET. The previous analyst recommendation was Buy. GOSS was trading at $0.8261 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present up...
- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 - - TORREY Phase 2 PAH Results Published in Lancet ...